Formulation of sorafenib in CXCR4-targeted PLGA NPs modified with AMD3100 efficiently delivers sorafenib into HCC and endothelial cells to achieve cytotoxicity and anti-angiogenic effect. The gene discussed is CXCR4; the disease is hepatocellular carcinoma.